CA
NZ
UK
AU
IND
US
Beyond Air reported Fiscal Year 2026 revenue of $7.7 million, a 107% year-on-year increase driven by the accelerating commercial rollout of LungFit PH, with customer retention exceeding 90% demonstrating strong clinical adoption and product satisfaction among hospital and neonatal care customers.
The FDA accepted Replimune's Class 1 resubmission of the Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma, setting an August 2, 2026 PDUFA goal date and indicating that a late-July advisory committee meeting is expected — maintaining the …
The Japan Patent Office has granted Can-Fite BioPharma a patent covering Namodenoson and other A3 adenosine receptor (A3AR) agonists for the treatment of obesity and weight reduction, strengthening the company's international intellectual property position for its oral anti-obesity programme.
• Jade Biosciences adds Mark Eisner, former Vir Biotechnology executive, to its board effective June 25, 2026.
• Vivos Therapeutics has extended its debt conversion agreement with Streeterville Capital until August 31, 2026.
• The company's Chief Executive Officer sold $933K of stock.
• Taysha Gene Therapies (NASDAQ: TSHA) has started an underwritten public offering priced at $200.0 million.
• Updated clinical trial results for a therapy targeting Duchenne muscular dystrophy-related heart complications have been reported.
• This includes shares of Common Stock with a par value of $0.001 per share.
• The company is raising approximately $50 million in a private placement financing to support its growth strategy.
Please wait processing your request...